The heavyweight in the Rosacea products, research and development market, Galderma, is to shed up to 450 jobs from its R&D Centre in Sophia Antipolis near Nice, France.
The press release cites a need to increase shareholder returns and a perceived movement in popularity away from topical creams to oral and injected treatments.
The can only be bad new for rosacea sufferers as it seems clear that Galderma is the largest pharmaceutical company interested in developing products for rosacea.
ZURICH (Reuters) – Nestle plans to cut up to 450 jobs at a Galderma research and development center in southern France, the Swiss company said on Thursday, as it seeks to make the underperforming skin health business more efficient.
Galderma, which Nestle took over from its joint venture partner L‘Oreal in 2014, will cut as many as 450 of 550 jobs at its R&D center in Sophia Antipolis near Nice.
Vevey-based Nestle is under pressure to improve efficiency and shareholder returns after years of slowing growth and its new Chief Executive Mark Schneider is expected to unveil his strategic priorities at an investor event next week.
Prescription medicines are moving away from creams towards injections or products taken orally and this shift is being reflected in changes to R&D, a Nestle spokesman said.
- Nestle now calling the shots at Galderma
- L’Oréal strong sales via Galderma and dermatology
- Galderma Big Profits Great for Texas